Cargando…

Identifying “at-risk” patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections

Detalles Bibliográficos
Autores principales:	Abdul-Aziz, Mohd H., Lipman, Jeffrey, Roberts, Jason A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697074/ https://www.ncbi.nlm.nih.gov/pubmed/29157264 http://dx.doi.org/10.1186/s13054-017-1871-2

Ejemplares similares

Continuous beta-lactam infusion in critically ill patients: the clinical evidence
por: Abdul-Aziz, Mohd H, et al.
Publicado: (2012)

Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review
por: Sime, Fekade Bruck, et al.
Publicado: (2012)

Beta-lactam antibiotics in continuous infusion in critically ill patients
por: Jeurissen, Axel, et al.
Publicado: (2010)

We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
por: Cotta, Menino Osbert, et al.
Publicado: (2016)

Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study
por: Barreto, Erin F., et al.
Publicado: (2021)

The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome
por: Scharf, Christina, et al.
Publicado: (2020)

743. Implementation of Beta-Lactam Therapeutic Drug Monitoring Programs in the Critically Ill: A Multicenter Mixed-Methods Study
por: Ausman, Sara, et al.
Publicado: (2022)

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
por: Barbier, François, et al.
Publicado: (2023)

Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy
por: Ulldemolins, Marta, et al.
Publicado: (2014)

Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
por: Veiga, Rui Pedro, et al.
Publicado: (2018)

The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients
por: Novy, Emmanuel, et al.
Publicado: (2023)

Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?
por: Barreto, Erin F., et al.
Publicado: (2021)

Update on Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Critically Ill Patients—A Narrative Review
por: Stašek, Jan, et al.
Publicado: (2023)

Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?
por: Van Herendael, Bruno, et al.
Publicado: (2012)

Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?
por: Guerra Valero, Yarmarly C, et al.
Publicado: (2022)

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018)

Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach
por: Maguigan, Kelly L., et al.
Publicado: (2021)

Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis
por: Pai Mangalore, Rekha, et al.
Publicado: (2022)

318. Beta-lactam Therapeutic Drug Monitoring Improves Attainment of Target Drug Levels in Critically Ill Patients
por: Ausman, Sara, et al.
Publicado: (2023)

Antifungal Dosing in Critically Ill Patients on Extracorporeal Membrane Oxygenation
por: Lyster, Haifa, et al.
Publicado: (2023)

Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations
por: Jager, Nynke G L, et al.
Publicado: (2020)

Broad-spectrum β-lactams in obese non-critically ill patients
por: Hites, M, et al.
Publicado: (2014)

How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?
por: Wong, Gloria, et al.
Publicado: (2014)

Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study
por: Ewoldt, Tim M. J., et al.
Publicado: (2022)

Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial
por: Ewoldt, Tim M. J., et al.
Publicado: (2022)

1805. Safety Outcomes Following Beta-Lactam use in Patients with a Documented Beta-Lactam Allergy
por: Rampersad, Daniel, et al.
Publicado: (2022)

Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients
por: Roberts, Jason A, et al.
Publicado: (2011)

Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams
por: Gonçalves-Pereira, Joao, et al.
Publicado: (2011)

A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance
por: Baptista, João Pedro, et al.
Publicado: (2011)

Progressive Sub-MIC Exposure of Klebsiella pneumoniae 43816 to Cephalothin Induces the Evolution of Beta-Lactam Resistance without Acquisition of Beta-Lactamase Genes
por: Anderson, Jasmine R., et al.
Publicado: (2023)

Beta lactam hypersensitivities
por: Azoury, Marie Eliane*, et al.
Publicado: (2014)

Use of beta-lactams antibiotics in ICU patients
por: Damas, M-P, et al.
Publicado: (2015)

Time Above All Else: Pharmacodynamic Analysis of Β-Lactams in Critically Ill Patients
por: Landmesser, Katherine, et al.
Publicado: (2021)

Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
por: Udy, Andrew A, et al.
Publicado: (2015)

Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)
por: Abdulla, Alan, et al.
Publicado: (2020)

Outcomes of Beta-Lactam Allergic and Non-Beta-Lactam Allergic Patients with Intra-Abdominal Infection: A Case–Control Study
por: Naciri, Tayma, et al.
Publicado: (2022)

Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction
por: Sime, Fekade B., et al.
Publicado: (2019)

B-lactams serum concentrations in critically ill cirrhotic patients: a matched-control study
por: Lheureux, O, et al.
Publicado: (2015)

Impact of an Extended Infusion Β-lactam Strategy on Outcomes in Critically Ill Patients with Pseudomonas Infections
por: Klinker, Kenneth, et al.
Publicado: (2017)

Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients
por: Sime, Fekade B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rgte4ii5762lhff05bcsulvgqi